122 related articles for article (PubMed ID: 37591367)
1. Ruthenium metallodendrimer against triple-negative breast cancer in mice.
Michlewska S; Wójkowska D; Watala C; Skiba E; Ortega P; de la Mata FJ; Bryszewska M; Ionov M
Nanomedicine; 2023 Sep; 53():102703. PubMed ID: 37591367
[TBL] [Abstract][Full Text] [Related]
2. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study.
Michlewska S; Maly M; Wójkowska D; Karolczak K; Skiba E; Hołota M; Kubczak M; Ortega P; Watala C; Javier de la Mata F; Bryszewska M; Ionov M
Int J Pharm; 2023 Apr; 636():122784. PubMed ID: 36858135
[TBL] [Abstract][Full Text] [Related]
3. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.
Montani M; Pazmay GVB; Hysi A; Lupidi G; Pettinari R; Gambini V; Tilio M; Marchetti F; Pettinari C; Ferraro S; Iezzi M; Marchini C; Amici A
Pharmacol Res; 2016 May; 107():282-290. PubMed ID: 27038531
[TBL] [Abstract][Full Text] [Related]
4. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
5. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
7. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells.
Lin M; Zou S; Liao X; Chen Y; Luo D; Ji L; Chao H
Chem Commun (Camb); 2021 May; 57(36):4408-4411. PubMed ID: 33949487
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model.
Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH
Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
11. Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem.
Ferraro MG; Bocchetti M; Riccardi C; Trifuoggi M; Paduano L; Montesarchio D; Misso G; Santamaria R; Piccolo M; Irace C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047448
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
13. New insights into ruthenium(II) metallodendrimers as anticancer drug nanocarriers: from synthesis to preclinic behaviour.
Maciel D; Nunes N; Santos F; Fan Y; Li G; Shen M; Tomás H; Shi X; Rodrigues J
J Mater Chem B; 2022 Nov; 10(43):8945-8959. PubMed ID: 36278302
[TBL] [Abstract][Full Text] [Related]
14. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
Fayad C; Audi H; Khnayzer RS; Daher CF
J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
[TBL] [Abstract][Full Text] [Related]
15. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
[TBL] [Abstract][Full Text] [Related]
16. A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.
Shen J; Kim HC; Wolfram J; Mu C; Zhang W; Liu H; Xie Y; Mai J; Zhang H; Li Z; Guevara M; Mao ZW; Shen H
Nano Lett; 2017 May; 17(5):2913-2920. PubMed ID: 28418672
[TBL] [Abstract][Full Text] [Related]
17. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Structure and Cytotoxicity of N,N and N,O-Coordinated Ru
Mukherjee A; Koley TS; Chakraborty A; Purkait K; Mukherjee A
Chem Asian J; 2021 Nov; 16(22):3729-3742. PubMed ID: 34549886
[TBL] [Abstract][Full Text] [Related]
19. Transport of the Ruthenium Complex [Ru(GA)(dppe)
Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
[TBL] [Abstract][Full Text] [Related]
20. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
Sanz Del Olmo N; Maroto-Diaz M; Quintana S; Gómez R; Holota M; Ionov M; Bryszewska M; Carmena MJ; Ortega P; Javier de la Mata F
Eur J Med Chem; 2020 Dec; 207():112695. PubMed ID: 32882608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
